Botox is the miracle wrinkle-remover but if many were expecting that its approval to treat overactive bladder would cause wrinkles on the foreheads of senior management at Minnesota incontinence treatment company Uroplasty, they were mistaken. At least for now. In a conference call with analysts to discuss the company’s third fiscal quarter earnings Thursday, Uroplasty […]
Reimbursement strategies are key to the success of any new technology. In fact, many believe that a U.S. Food and Drug Administration approval is crucial to launch a product, but its market success hinges on adequate reimbursement. And that has been the experience of Minnetonka, Minnesota-based Uroplasty (NASDAQCM:UPI). In 2004, it licensed the only percutaneous […]
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
A Minnesota urinary incontinence treatment company is now expanding to treat that other voiding dysfunction. Uroplasty (NASDAQ CM:UPI) announced Thursday that it is testing its Urgent PC Neuromodulation treatment for overactive bladders to now treat fecal incontinence. The company will launch a clinical trial in late summer in the U.S. The office-based, minimally invasive treatment is […]
Urinary incontinence products maker Uroplasty (NASDAQ:UPI) announced Monday that two private payers have agreed to cover its overactive bladder treatment. The Minnetonka, Minnesota-based urology firm has been winning coverage for its Urgent PC Neuromodulation treatment, which began with getting reimbursement from Medicare in November. And Wall Street has noticed. In the past year, the stock […]
Private insurers and Medicare regional carriers who decided to cover Uroplasty’s primary urinary incontinence product and other positive developments buoyed Uroplasty Inc.’s fiscal fourth-quarter sales numbers. The Minnetonka, Minnesota company announced that in the quarter ended March 31, sales jumped 35 percent to $4.01 million from $2.98 million in the same quarter a year ago. […]
Uroplasty‘s performance finally “began to reflect the potential of the company” in the third quarter, CEO David Kaysen said Thursday during the company’s earnings call. The Minnetonka, Minnesota, device company ramped up its sales force, won over five new regional Medicare carriers, and boosted global sales by 14 percent to $3.5 million during the quarter, […]
GT Urological has raised $4.56 million from the sale of equity, according to documents filed with the Securities and Exchange Commission.
Uroplasty Inc. (NASDAQ:UPI) suffered a setback for insurance coverage of its Urgent PC Neuromodulation system. After Jan. 3, use of the posterior tibial nerve stimulation device will no longer be paid for by National Government Services, a regional Medicare carrier that operates in Connecticut, Indiana, Kentucky and New York, the company revealed today. The loss […]
An additional regional Medicare carrier is now covering overactive bladder treatment using Uroplasty Inc. (NASDAQ:UPI) Urgent PC Neuromodulation System. Palmetto GBA for California, Nevada and Hawaii now covers posterior tibial nerve stimulation using the device, according to the company. Lawrence, Kansas-based Palmetto GBA LLC is a contracted company that pays claims for Medicare professional services. The coverage approval […]
Do you hear that? That's the sound of some mighty back-slapping at Uroplasty Inc.'s (NASDAQ:UPI) headquarters in Minnetonka, Minnesota. After winning Medicare reimbursement Wednesday for its urinary incontinence therapy, the company has seen its stock price jump more than 20 percent to around $5.35 per share.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Uroplasty Inc. lands reimbursement status from the Centers for Medicare and Medicaid Services for its posterior tibial nerve stimulation device for treating overactive bladder. Centers for Medicare and Medicaid Services awarded reimbursement status to Uroplasty Inc.’s (NSDQ:UPI) Urgent PC Neuromodulation System. When companies’ products are approved for coverage by the governmental agency, private-pay insurance companies […]
Here are some news/notes on a day in MedCity, Minnesota: Uroplasty Inc.’s stock price jumped 4.6 percent Tuesday after the company announced positive results from study of its incontinence treatment, according to the Minneapolis-St. Paul Business Journal. The movement comes after the Minnetonka-based medical device developer reported favorable results from a large study to be […]
